Our study confirmed that the 18F-PSMA-1007 PET/CT variables, SUVmin, SUVmax, and SUVmean, can be used as semi-quantitative “imaging biomarkers” for both PSA levels (<20 vs. ≥20 ng/mL) and pathological malignancy (GS <8 vs. ≥8) discrimination among patients with PCa. The gene discussed is KLK3; the disease is posterior cortical atrophy.